Evaluation of 18F-MISO-PET detectable changes in proliferation and dispersion of hypoxic subvolume in head and neck cancer in patients undergoing radio(chemo)therapy - F-MISO-PET

Klinik für Strahlenheilkunde, Freiburg0 个研究点目标入组 33 人开始时间: 2015年8月20日最近更新: 2024年8月19日

适应症

试验速览

暂无简介。

•Histo - or cytologically secured squamous cell carcinoma of the oral cavity, hypopharynx or larynx
•Stage III / IV (M0)
•ECOG performance status 0 or 1
•Two-dimensionally measurable tumor> = 2cm in at least one dimension
•Age> = 18 years
•Adequate hematologic function • (Hb> 9 g / dl, platelets> = 100X 10 9 / l, ANC> = 1.5 X 10 9 / L)
•Adequate renal function (creatinine - clearance> = 50 ml / min)
•Adequate liver function (AST, ALT and total bilirubin <= 2X ULN)
•Adequate metabolic function (including Mg> = LLN)
•Written consent

•Previous anti-EGFR antibody therapy or treatment with small molecule tyrosine kinase inhibitors
•Previous surgery, chemotherapy or radiation for in the relevant study malignancies
•Prophylactic tracheostomy
•Other known clinically significant diseases (cardiovascular, pulmonary, infections such as HIV, HCV, HBV, ...)
•Pregnant or lactating women
•To provide each type of disability, which affects the compliance or ability of the patient, written consent

发起方

Klinik für Strahlenheilkunde, Freiburg